AGIO - Agios Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Agios Pharmaceuticals, Inc.

88 Sidney Street
Cambridge, MA 02139
United States
617-649-8600
http://www.agios.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees382

Key Executives

NameTitlePayExercisedYear Born
Dr. David P. SchenkeinCEO, Pres & Director918.73k2.36M1957
Dr. Lewis Clayton CantleyCo-Founder & Member of Scientific Advisory Board48.12kN/A1949
Mr. Andrew HirschChief Financial Officer303.37kN/A1971
Dr. Scott A. Biller Ph.D.Chief Scientific Officer593.87k5.01M1956
Dr. Christopher J. BowdenChief Medical Officer619.63kN/A1961
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Corporate Governance

Agios Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2018 is 5. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.